deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02926196

Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (A-Brave)

Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab: A Phase III Randomized Trial. Sponsor: Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Università di Padova

Sponsor: Dipartimento di scienze chirurgiche, Oncologiche e Gastroenterologiche

Conditions Triple Negative Breast Neoplasms
Interventions MSB0010718C
Updated 17 times since 2017 Last updated: Dec 5, 2025 Started: Jun 17, 2016 Primary completion: Jun 30, 2024 Completion: Oct 9, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02926196, this PHASE3 trial focuses on Triple Negative Breast Neoplasms and remains completed. Sponsored by Dipartimento di scienze chirurgiche, Oncologiche e Gastroenterologiche, it has been updated 17 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jul 2017 · 6 months · monthly snapshot~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Jul 2019 · 11 months · monthly snapshot~Jul 2019 – ~Oct 2020 · 15 months · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~May 2022 · 7 months · monthly snapshot~May 2022 – ~Nov 2023 · 18 months · monthly snapshot~Nov 2023 – ~Apr 2024 · 5 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Sep 2025 · 9 months · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – present · 4 months · monthly snapshot

Change History

17 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Sep 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE3

  3. Dec 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 12 earlier versions

  1. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Nov 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE3

  3. May 2022 — Nov 2023 [monthly]

    Active Not Recruiting PHASE3

  4. Oct 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE3

  5. Jan 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE3

  6. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  7. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  8. Jul 2019 — Oct 2020 [monthly]

    Recruiting PHASE3

  9. Aug 2018 — Jul 2019 [monthly]

    Recruiting PHASE3

  10. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  11. Jul 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

  12. Jan 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

    First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dipartimento di scienze chirurgiche, Oncologiche e Gastroenterologiche
  • Istituto Oncologico Veneto IRCCS
  • University of Padova
Data source: Istituto Oncologico Veneto IRCCS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ancona, Italy , Asti, Italy , Aviano, Italy , Bath, United Kingdom , Belluno, Italy , Bergamo, Italy , Blackpool, United Kingdom , Bologna, Italy , Bolzano, Italy , Brescia, Italy and 51 more locations